Stock Comparison

PFE vs TWST

Pfizer Inc vs Twist Bioscience Corp

The Verdict

TWST takes this one.

PFE

Pfizer Inc

4.0

out of 10

Proceed with Caution

Winner

TWST

Twist Bioscience Corp

7.0

out of 10

Solid Pick

Head-to-Head

$146.4B

Market Cap

$4.2B

19.5

P/E Ratio

14.7

11.8%

Profit Margin

-19.9%

8.4%

Return on Equity

-17.5%

0.7

Debt-to-Equity

0.5

Moderate

Overall Risk

Aggressive

4.0

DVR Score

7.0

The Deep Dive

PFE4.0/10

Pfizer Inc. remains a mature, large-cap pharmaceutical company with limited potential for the requested 10x growth within 3-5 years, which would require a market cap exceeding $1.4 trillion. While Q1 2026 results showed revenue of $14.45B and adjusted EPS of $0.75, both beating estimates, YoY revenue growth was modest at +5.4% and adjusted EPS declined -18%. Strategic legal wins for VYNDAQEL and C...

Full PFE Analysis

TWST7.0/10

Twist Bioscience maintains its high-risk, high-reward profile with compelling 10x growth potential, driven by its unique silicon-based DNA synthesis platform and strategic entry into DNA data storage. Q2 FY26 results confirmed strong revenue growth and expanded clonal gene offerings, reinforcing its market opportunity and technological moat. However, the reported EPS miss for Q2 FY26 and ongoing i...

Full TWST Analysis

Want More Comparisons?

Run any stock through our deep value analyzer.

Analyze Any Stock →

Not Financial Advice

This comparison is for educational purposes only. We are not financial advisors. Always do your own research and consult a qualified advisor before investing.